GenePHIT Phase 2 baseline characteristics: a double blind, placebo-controlled trial to assess safety and efficacy of AB-1002 gene therapy in heart failure with reduced ejection fraction
29 August 2026 (17:10 - 17:20)
Organised by: 
About the speaker
The Christ Hospital, Cincinnati (United States of America)
4 More presentations in this session
Doctor C. Yang (Shanghai, CN)
Assistant Professor I. Rodean (Targu Mures, RO)
Access the full session
The Event
ESC Congress 2026
29 August 2026
17:10 CET
You may be interested in
Congress Presentation
Congress Session
Congress Presentation
